In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Pfizer to buy Sanofi-Aventis' share of Exubera for $1.3bn

Executive Summary

For $1.3bn, Pfizer is acquiring Sanofi-Aventis's worldwide rights to Exubera, an inhaled fast-acting dry powder human insulin product originally co-developed, co-promoted, and co-manufactured by the two companies under a November 1998 agreement.

Deal Industry
  • Medical Devices
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)
    • Product Purchase

Related Companies